文献速递帕金森病与运动障碍认知障碍与痴呆

Aβ42下降预测早期帕金森病多巴抵抗性步态进展

Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.
PubMed 文献 · Neurology · 2017-03-22

这项前瞻性观察研究在108例帕金森病患者和130例年龄匹配对照中纵向开展定量步态分析,其中44例患者接受腰椎穿刺检测脑脊液生物标志物。结果显示,基线脑脊液Aβ42降低可预测诊断后3年内多巴抵抗性步态特征的恶化,且独立于年龄和认知。

要点

  • 基线脑脊液Aβ42降低可预测早期帕金森病诊断后3年内多巴抵抗性步态恶化。
  • Aβ42独立解释单任务步态时间变异性和双任务步长变异性进展最多12%。
  • 该关联独立于年龄和认知,提示淀粉样蛋白病理参与运动控制网络。

核心结论

  • 脑脊液Aβ42降低与早期帕金森病多巴抵抗性步态进展相关,提示Aβ代谢紊乱可能是早期帕金森病多巴抵抗性步态障碍的生物标志物。

研究设计与样本

  • 前瞻性观察研究,纳入108例帕金森病患者和130例年龄匹配对照,进行纵向定量步态分析(GAITRite仪器化步道)。
  • 其中44例帕金森病患者接受腰椎穿刺,检测Aβ42、Aβ40、t-tau、p-tau181和α-突触核蛋白。
  • 采用线性混合模型分析脑脊液生物标志物与多巴抵抗性步态特征的关联。

主要发现

  • 基线脑脊液Aβ42低(Aβ40较低程度亦如此)预测诊断后前3年步态特征下降。
  • Aβ42独立解释单任务步态时间变异性进展最多12%,以及双任务步长变异性进展最多12%。
  • 上述发现独立于年龄和认知。

临床怎么用

  • 对早期帕金森病患者,脑脊液Aβ42可能有助于识别多巴抵抗性步态障碍进展风险较高者。
  • 离散步态特征的进展可能作为病理和疾病进展的临床生物标志物。
  • 研究提示针对降低淀粉样蛋白负荷的干预或许可减轻早期帕金森病步态障碍及潜在跌倒风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This prospective observational study investigates the role of CSF biomarkers in predicting progression of dopa-resistant gait impairments in Parkinson disease (PD) in the first 36 months from diagnosis. METHODS: Quantitative gait analysis was carried out longitudinally using an instrumented walkway (GAITRite) in 108 people with PD and 130 age-matched controls. A subgroup of 44 people with PD underwent lumbar puncture from which a battery of CSF biomarkers was measured: β-amyloid 1-42 and 1-40 (Aβ42 and Aβ40), total and phosphorylated tau protein (t-tau/p-tau181), and α-synuclein (αSyn). Linear mixed models examined the association between CSF and dopa-resistant gait characteristics (defined as substantial progression despite optimal medication). RESULTS: Low baseline CSF Aβ42, and to a lesser extend Aβ40, predicted decline in gait characteristics in the first 3 years following diagnosis, independently explaining up to 12% of progression of step time variability (single task) and step length variability (dual-task). Interestingly, these findings were independent of age and cognition. CONCLUSIONS: These findings implicate underlying amyloid pathology in neural networks involved in locomotor control. Results suggest that disturbed Aβ metabolism may be a biomarker for dopa-resistant gait impairments in early PD. Our findings raise interesting questions regarding therapeutic interventions such as compounds or molecules aimed at reducing amyloid burden to mitigate gait disturbance in early PD and potentially falls risk. Finally, progression of discrete gait characteristics suggests they may have potential as clinical biomarkers of pathology and disease progression.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rochester L, Galna B, Lord S, et al. Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease. Neurology. 2017. PMID: 28330963. doi:10.1212/WNL.0000000000003840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。